Seeking Alpha

J&J (JNJ) won't enforce its patents on its HIV/AIDS drug Prezista in sub-Saharan Africa and...

J&J (JNJ) won't enforce its patents on its HIV/AIDS drug Prezista in sub-Saharan Africa and other poor countries, allowing generic pharmaceutical companies to manufacture cheap versions of the drug as long as the quality remains high. However, J&J won't share its IP in the new Medicines Patent Pool, saying it wants "to reserve the right to reinforce patents."
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs